Talaris Therapeutics, Inc. launches an IPO.

IPO of Talaris Therapeutics, Inc. (TALS) will take place on May 6, 2021. Talaris Therapeutics is a late-clinical stage, cell therapy company that develops an innovative method of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The company’s goal is to change the standards of treatment for organ transplantation, severe autoimmune diseases and some severe non-malignant blood diseases, immune and metabolic disorders. The main product of the company is FCR001, which is a novel allogenic cell therapy comprised of stem and immune cells procured from a healthy donor.

The estimated valuation of the company after the IPO will be $415 million.

The listed bookrunners of the IPO are Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities.